Zentalis Stock Today

ZNTL Stock  USD 17.15  0.68  3.81%   

Market Performance

0 of 100

Odds Of Distress

Less than 26

Zentalis PharmaceuticalsL is selling for 17.15 as of the 27th of March 2023. This is a -3.81 percent down since the beginning of the trading day. The stock's lowest day price was 16.35. Zentalis PharmaceuticalsL has about a 26 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Zentalis PharmaceuticalsLlc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of September 2022 and ending today, the 27th of March 2023. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of April 2020
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. The company has 59.42 M outstanding shares of which 8.08 M shares are at this time shorted by private and institutional investors with about 16.77 trading days to cover. More on Zentalis PharmaceuticalsLlc

Moving together with Zentalis PharmaceuticalsL

+0.69ACRXAcelRx Pharmaceuticals Earnings Call This WeekPairCorr

Moving against Zentalis PharmaceuticalsL

-0.55AVDLAvadel Pharmaceuticals Report 30th of March 2023 PairCorr
-0.49ABBVAbbVie Inc Fiscal Quarter End 31st of March 2023 PairCorr

Zentalis PharmaceuticalsL Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Zentalis PharmaceuticalsL's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Zentalis PharmaceuticalsL or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Fama & French Classification
Average Analyst Recommendation
Analysts covering Zentalis PharmaceuticalsL report their recommendations after researching Zentalis PharmaceuticalsL's financial statements, talking to executives and customers, or listening in on Zentalis PharmaceuticalsL's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Zentalis PharmaceuticalsL. The Zentalis consensus assessment is calculated by taking the average forecast from all of the analysts covering Zentalis PharmaceuticalsL.
Strong Buy10 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Zentalis PharmaceuticalsL based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Zentalis PharmaceuticalsL financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted43.4 M52.9 M
Significantly Down
Slightly volatile
Weighted Average Shares43.4 M52.9 M
Significantly Down
Slightly volatile
Current Liabilities47.2 M56.6 M
Fairly Down
Slightly volatile
Total Liabilities85 M105.3 M
Significantly Down
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Total Debt41.3 M45.2 M
Significantly Down
Slightly volatile
Current Assets381.8 M451.9 M
Fairly Down
Slightly volatile
Total Assets456.1 M539.3 M
Fairly Down
Slightly volatile
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Zentalis PharmaceuticalsL's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Zentalis PharmaceuticalsL's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Zentalis PharmaceuticalsL's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zentalis PharmaceuticalsL's financial leverage. It provides some insight into what part of Zentalis PharmaceuticalsL's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Zentalis PharmaceuticalsL's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Zentalis PharmaceuticalsL deploys its capital and how much of that capital is borrowed.
Zentalis PharmaceuticalsL cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 46.8 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Zentalis PharmaceuticalsL has a current ratio of 9.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Zentalis PharmaceuticalsL until it has trouble settling it off, either with new capital or with free cash flow. So, Zentalis PharmaceuticalsL's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zentalis PharmaceuticalsL sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zentalis to invest in growth at high rates of return. When we think about Zentalis PharmaceuticalsL's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(168.06 Million)
Zentalis PharmaceuticalsLlc (ZNTL) is traded on NASDAQ Exchange in USA. It is located in 1359 Broadway, New York, NY, United States, 10018 and employs 156 people. Zentalis PharmaceuticalsL is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zentalis PharmaceuticalsL's market, we take the total number of its shares issued and multiply it by Zentalis PharmaceuticalsL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Zentalis PharmaceuticalsL conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.42 M outstanding shares of which 8.08 M shares are at this time shorted by private and institutional investors with about 16.77 trading days to cover. Zentalis PharmaceuticalsLlc currently holds about 455.22 M in cash with (163.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99.
Check Zentalis PharmaceuticalsL Probability Of Bankruptcy
Zentalis PharmaceuticalsL owns a total of 59.42 Million outstanding shares. The majority of Zentalis PharmaceuticalsL outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zentalis PharmaceuticalsL to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zentalis PharmaceuticalsLlc. Please pay attention to any change in the institutional holdings of Zentalis PharmaceuticalsL as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation

Check Zentalis Ownership Details

Zentalis Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Zentalis PharmaceuticalsL jumping above the current price in 90 days from now is about 91.72%. The Zentalis PharmaceuticalsLlc probability density function shows the probability of Zentalis PharmaceuticalsL stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1063. This usually means Zentalis PharmaceuticalsLlc market returns are very sensitive to returns on the market. As the market goes up or down, Zentalis PharmaceuticalsL is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Zentalis PharmaceuticalsL is significantly underperforming NYSE Composite.
  Odds Below 17.15HorizonTargetOdds Above 17.15
8.23%90 days
Based on a normal probability distribution, the odds of Zentalis PharmaceuticalsL to move above the current price in 90 days from now is about 91.72 (This Zentalis PharmaceuticalsLlc probability density function shows the probability of Zentalis Stock to fall within a particular range of prices over 90 days) .

Zentalis Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Zentalis PharmaceuticalsL that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Zentalis PharmaceuticalsL's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Zentalis PharmaceuticalsL's value.
InstituionLast TransactionTypeSharesValue
Matrix Capital Management Company Lp2022-12-31Common Shares9.2 M185.3 M
Fmr Llc2022-12-31Common Shares7.9 M159.3 M
Avidity Partners Management Lp2022-12-31Common Shares5.2 M103.7 M
Vanguard Group Inc2022-12-31Common Shares4.2 M83.8 M
Wellington Management Group Llp2022-12-31Common Shares3.6 M72.9 M
Blackrock Inc2022-12-31Common Shares3.5 M69.9 M
State Street Corp2022-12-31Common Shares3.1 M62.1 M
Capital International Investors2022-12-31Common SharesM61.4 M
Viking Global Investors Lp2022-06-30Common SharesM56.9 M
Tybourne Capital Management Hk Ltd2022-12-31Common Shares2.2 M44.9 M
T Rowe Price Investment Management Inc2022-12-31Common Shares2.2 M44.5 M
View Zentalis PharmaceuticalsL Diagnostics

Zentalis PharmaceuticalsL Historical Income Statement

Zentalis PharmaceuticalsLlc Income Statement is one of the three primary financial statements used for reporting Zentalis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Zentalis PharmaceuticalsL revenue and expense. Zentalis PharmaceuticalsL Income Statement primarily focuses on the company's revenues and expenses during a particular period.
The value of Consolidated Income is estimated to slide to about (243.4 M). The value of Earning Before Interest and Taxes EBIT is expected to slide to about (243.5 M) View More Fundamentals

Zentalis Stock Against Markets

Picking the right benchmark for Zentalis PharmaceuticalsL stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Zentalis PharmaceuticalsL stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Zentalis PharmaceuticalsL is critical whether you are bullish or bearish towards Zentalis PharmaceuticalsLlc at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Zentalis PharmaceuticalsL without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now


Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Zentalis PharmaceuticalsL Corporate Management

Elected by the shareholders, the Zentalis PharmaceuticalsL's board of directors comprises two types of representatives: Zentalis PharmaceuticalsL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zentalis. The board's role is to monitor Zentalis PharmaceuticalsL's management team and ensure that shareholders' interests are well served. Zentalis PharmaceuticalsL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zentalis PharmaceuticalsL's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cameron MBAPres CoFounderProfile
Kevin BunkerCoFounder OfficerProfile
Carrie MDChief OfficerProfile
Adam LevyVP RelationsProfile
Mark LacknerChief StrategyProfile
Melissa MBACFO TreasurerProfile
Kimberly MDCEO DirectorProfile

How to buy Zentalis Stock?

Before investing in Zentalis PharmaceuticalsL, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Zentalis PharmaceuticalsL. To buy Zentalis PharmaceuticalsL stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Zentalis PharmaceuticalsL. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Zentalis PharmaceuticalsL stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Zentalis PharmaceuticalsLlc stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Zentalis PharmaceuticalsLlc stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Zentalis PharmaceuticalsLlc, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Zentalis Stock please use our How to Invest in Zentalis PharmaceuticalsL guide.

Already Invested in Zentalis PharmaceuticalsLlc?

The danger of trading Zentalis PharmaceuticalsLlc is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zentalis PharmaceuticalsL is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zentalis PharmaceuticalsL. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zentalis PharmaceuticalsL is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Your Current Watchlist. For more information on how to buy Zentalis Stock please use our How to buy in Zentalis Stock guide. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for analysis

When running Zentalis PharmaceuticalsL price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Directory
Find actively traded corporate debentures issued by US companies
Bond Directory
Find actively traded corporate debentures issued by US companies
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine Zentalis PharmaceuticalsL value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.